Intravenous and volatile anesthetics
Treatment with intravenous anesthetics such as ketamine and thiopental stimulate lung and liver metastases in animal models [
65], with one study showing that ketamine and thiopental increase LTR or lung metastasis via NK cell suppression in a rat model [
66]. Similarly, the volatile anesthetic halothane can stimulate lung and liver metastases [
65]. In contrast, sevoflurane suppresses hypoxia-inducible growth and metastasis of lung cancer cells by inhibiting HIF-1α, which is involved in the p38 mitogen-activated protein kinase (MAPK) signaling pathway [
67]. Another study has shown that sevoflurane increases proliferation, migration, and invasion of estrogen receptor (ER)-positive breast cancer cells, as well as proliferation and migration of ER-negative cells [
68]. Furthermore, serum from patients who received sevoflurane and an opioid for breast cancer surgery did not inhibit proliferation of ER-negative breast cancer cells, but serum from those receiving propofol and paravertebral anesthesia did inhibit proliferation [
69].
Exposure to sevoflurane but not total intravenous anesthesia (TIVA) by propofol results in increased prosurvival proteins such as cytoplasmic HIF-2α and nuclear p38 MAPK in head and neck squamous cell carcinoma [
70]. Isoflurane is associated with increased HIF-1α levels and increased prostate cancer cell proliferation and migration [
71]. In contrast, isoflurane-induced HIF-1α activation is prevented by propofol, which is associated with partial reduction of malignant activities by cancer cells [
71]. Additionally, tumor growth in inoculated in mice is suppressed by propofol, which may have immune-mediated antitumor effects [
41]. Isoflurane increases the malignant potential of ovarian cancer cells through the upregulation of insulin-like growth factor (IGF)-1 and its receptor IGF-1R, as well as VEGF, angiopoietin-1, MMP-2, and MMP-9 [
72]. Furthermore, isoflurane exposure leads to apoptotic resistance in human colon cancer cells through a caveolin-1-dependent mechanism [
73]. Nitrous oxide (N
2O) impairs DNA, purine, and thymidylate synthesis, which can itself cause of oncogenesis [
74]. A tumor-bearing mouse model has shown that N
2O suppresses chemotaxis, which may be the most potent stimulator of postsurgical lung and liver metastasis development [
18,
65]. However, it is unlikely that N
2O increases the risk of cancer recurrence compared to that of nitrogen after colorectal surgery [
75].
Opioids and other agents
Commonly used opioid analgesics may affect tumor development through their modulation of cell proliferation and cell death [
76‐
78]. It has been suggested that opioids suppress the immune response because various immune competent cells express opioid receptors and induce apoptosis during opioid alkaloid treatment. Tumor growth promotion is mediated through AKT and extracellular signal–regulated kinase (ERK) signaling cascades, whereas death-promoting effects are mediated through NF-κB inhibition, increased Fas expression, p53 stabilization, activation of p38, and c-Jun-N-terminal kinase (JNK) [
79]. It is likely that opioid-induced cell proliferation and cell death depend on opioid concentration or exposure duration. Tumor growth promotion occurs with low concentrations or single doses of opioids, whereas growth inhibition occurs with chronic opioid use or relatively high drug concentrations [
80].
Breast cancer cells treated with low morphine concentrations induce naloxone (NX)-sensitive, concentration-dependent increases in GTPase activity, with morphine signals being transmitted by opioid receptors via a G protein [
81]. In contrast, the anti-proliferative effects of morphine are not eliminated by NX. Morphine-induced p53 phosphorylation and stabilization in breast cancer cells expressing wild type p53 causes increased production of p53-dependent proteins, including p21, Bax, and Fas [
81]. These findings suggest that morphine may reduce growth of certain cancer cells through p53 activation. Additionally, morphine has been shown to inhibit expression and secretion of MMP-2 and MMP-9 in breast cancer cells in a time-dependent and concentration-dependent manner. This MMP activity is not reversible with NX, indicating that attenuation of MMP secretion by morphine is not mediated by opioid receptors, but is controlled by the NO system [
82].
Based on preclinical and clinical studies, differences in recurrence rates for certain cancers may be due to immune suppression and direct effects of volatile anesthesia and opioids on cancer growth. Overexpression of the μ-opioid receptor (MOR), which promotes tumor growth and metastasis, is observed in several human cancers [
83]. AKT and mTOR activation, cell proliferation, and extravasation are all related to MOR overexpression in a nude mouse model of non-small cell lung cancer (NSCLC) [
84]. In addition, a potential direct effect of opiates has been observed in animal models that show MOR regulating tumorigenicity in Lewis lung carcinoma (LLC) [
85]. Similarly, a study has shown the potential direct effect of opioids on MOR through growth factor-signaling proliferation, migration, and epithelial–mesenchymal transition during lung cancer progression [
86]. Treatment with methylnaltrexone (MNTX), a peripheral opioid antagonist, inhibits LLC invasion and anchorage-independent growth, whereas continuous MNTX infusion decreases primary LLC tumor growth and lung metastasis [
85]. Further, MNTX inhibits opioid-induced proliferation and migration of pulmonary microvascular endothelial cells through its effects on VEGF receptor phosphorylation and transactivation and inhibition of Rho A activation [
87]. Clinically, MNTX treatment is associated with increased overall survival in patients with advanced cancer; this finding supports the hypothesis that MOR is involved in tumor progression and that MNTX may target MOR [
88]. Because morphine reciprocally transactivates MOR and VEGF receptors, MOR-knockout mice do not grow significant lung cancer tumors; MNTX treatment markedly decreases tumor growth in experimental mouse models [
89].
Morphine at clinical blood concentrations stimulates proliferation and angiogenesis of microvascular endothelial cells by activating MAPK/ERK phosphorylation using Gi/Go-coupled G protein receptors and NO. Effects include apoptotic inhibition of apoptosis through AKT activation and promotion of cell cycle progression through increased cyclin D1 [
76]. Morphine at clinically useful doses promotes tumor neovascularization and progression in a xenograft model of a human breast tumor [
76]. Similarly, clinical doses of morphine promote angiogenesis and tumor progression in ER-negative breast cancer cells in vitro and in vivo [
90]. Morphine is also able to stimulate in vitro vascular endothelial cell proliferation, which is mediated by the MAPK pathway [
91]. It is likely that MOR has an important role in angiogenesis and oncogenic signaling.
Preoperative and postoperative morphine administration for analgesia decreases the tumor promotion surgical effects in a rat model [
92]. Preoperative and postoperative morphine treatment in rats significantly reduces surgery-induced corticosterone increases [
93]. This finding suggests that preoperative morphine may play a key role in protecting against surgery-induced metastasis. Intraoperative opioid use has been associated with increased overall survival in patients with stage I but not stage II or III NSCLC [
94].
Fentanyl has demonstrated antitumor-like effects in colorectal cancer cells in vitro. Its use is associated with decreased cell clone formation, and inhibition of cell migration and invasion through inhibition of negative regulation of E26 transformation–specific sequence-1 on serine/threonine kinase protein kinase B-raf (BRAF)-activated lncRNA [
95]. Another study has shown that fentanyl inhibits tumor growth and cell invasion in colorectal cancer by downregulating miR-182 and MMP-9 expression using β-catenin [
96]. A recent study showed that sufentanil does not affect the apoptosis rate or cell cycle distribution of colon and pancreatic cancer cells at clinical concentrations in vitro [
97].
Although benefits of using RA to avoid opioids have been suggested by clinical trials, it is unclear whether benefits result from withholding opioids or adding RA. Morphine administration may be beneficial for pain control, but MOR is involved in tumor progression for certain cancer cell types. Opioids may play a crucial role in cancer metastasis and recurrence, but this effect varies by cancer cell type [
98]. Prostaglandin E
2, a soluble, tumor-derived angiogenic factor, is associated with VEGF-independent angiogenesis. PGE
2 production in preclinical breast and colon cancer models is controlled by COX-2 expression, and COX-2 inhibition enhances VEGF blockade to inhibit angiogenesis, tumor growth, and metastasis to increase overall survival [
99]. Previous case control studies show that selective COX-2 inhibitors reduce breast and colorectal cancer risk [
100,
101], with the NSAID analgesic ketorolac being associated with a five-fold reduction in cancer relapse in the first few years after breast surgery [
102]. Because transient and systemic inflammation following surgery may be involved in metastatic tumor seeding and angiogenesis, perioperative antiinflammatory agents may be used to block those effects.
Local anesthetics
Although local anesthetics suppress proliferation of several cancer cell types, their mechanism is unknown. Local anesthetics block voltage-gated sodium channels (VGSC), which are transmembrane proteins composed of one pore-forming α-unit and one or more auxiliary β-units. Cancer cells express an array of ion channels that their terminally differentiated counterparts do not [
103]. VGSCs are highly expressed and active in breast, colon, and lung cancers, and local anesthetics that cause channel blockade may inhibit tumor growth. In fact, lidocaine, ropivacaine, and bupivacaine, which inhibit proliferation and differentiation, are cytotoxic to mesenchymal stem cells (MSCs) in vitro, and have key functions for tumor growth and metastatic formation in cancer cells [
104].
Locally administered lidocaine directly inhibits epidermal growth factor receptor (EGFR), which is a potential target for anticancer drugs. Clinical concentrations of lidocaine have been shown to inhibit serum-induced and EGF-induced proliferation in human tongue cancer cells in association with tyrosine kinase activity of EGFR [
105]. One study that assessed the direct effect of local anesthetics showed that clinically useful concentrations of lidocaine and bupivacaine induce apoptosis in breast cancer cells in vitro and in vivo, suggesting a potential benefit of local anesthetics for breast cancer surgery [
106]. Lidocaine and tetracaine, which both inhibit kinesin motor proteins, reduce formation and function of tubulin micro-tentacles; thus, these drugs may have a novel ability to decrease metastatic spread in breast cancer cells [
107]. Lidocaine use at clinical concentrations results in DNA demethylation from ER-positive and ER-negative breast cancer cells in vitro [
108]. Although infiltrative anesthetics have the same membrane-stabilizing activity as lidocaine, they effectively inhibit the invasive ability of human cancer cells at the 5 mM to 20 mM concentrations used in surgery [
109]. Lidocaine additionally blocks human cancer cell invasion through modulation of intracellular Ca
2+ concentrations and inhibition of ectodomain shedding of heparin-binding epidermal growth factor from cell surfaces [
109]. Furthermore, lidocaine, ropivacaine, and bupivacaine all reduce MSC proliferation at 100 μM concentrations by causing cell cycle delay or arrest at the G
0/1-S phase; this feature is the reason why local anesthetics are used perioperatively for treatment of patients with cancer [
96]. In contrast, ropivacaine and bupivacaine do cause apoptosis and cell cycle distribution at clinical concentrations for colon and pancreatic cancer cells in vitro; their only antitumor growth activity occurs at high concentrations [
97]. Based on these findings, it is unlikely that the observed protective effects of RA on CMI result from direct effects on cancer cells. The overall effect of anesthetic agents on tumor development is summarized in Table
3.
Table 3
Effect of anesthetic agents on tumor development
Intravenous |
Ketamine | Stimulator of lung and liver metastasis [ 65] Increase in lung tumor retention or lung metastasis [ 66] Increase in lung tumor retention or lung metastasis [ 66] Inhibition of HIF-1α activation [ 71] Prevention of isoflurane-induced HIF-1α activation [ 71] Antitumor effect [ 18] | |
Thiopental |
Propofol |
Volatile anesthetics | | |
Halothane | Stimulator of lung and liver metastasis [ 65] Suppression of hypoxia-induced growth and metastasis of lung cancer cells [ 35] Increased proliferation, migration, and invasion of breast cancer cells [ 77] | Serum from sevoflurane/opioid anesthesia-analgesia for breast cancer surgery attenuates the inhibition of breast cancer cell proliferation [ 69] Increased expression of pro-oncogenic protein markers in head and neck squamous cell carcinoma cells [ 70] |
Sevoflurane |
Isoflurane | Upregulation of HIF-1α in prostate cancer cell line [ 71] Increase in malignant potential of ovarian cancer cells [ 72] Resistance against apoptosis via a Cav-1-dependent mechanism in cancer cells [ 73] | |
Nitrous oxide | Suppression of neutrophil chemotaxis, potentially facilitating the spread of cancer [ 18] Potent stimulator of lung and liver metastasis [ 65] | No effect on colorectal carcinoma recurrence [ 87] |
Opioids |
Morphine | Promotion of tumor growth (single-dose or low dose) [ 81] Involvement of MOR in tumor development [ 85‐ 87] Promotion of tumor growth and metastasis by MOR overexpression [ 85] Proangiogenic and proliferative effects in breast cancer xenografts [ 76, 90] Increase in endothelial cell proliferation expressed with mu3 opioid receptor [ 91] Stimulation of Rho A and Src activation downstream of the VEGFR [ 88] Direct effect of morphine on breast cancer cell migration via NET1 [ 68] Reduction in growth of certain tumors in part through activation of p53 [ 82] Attenuation of MMP secretion under the control of nitric oxide system [ 83] Beneficial effects on surgery-induced increases in metastasis by pre-surgical administration of morphine [ 93] Protective effect against metastasis development [ 34] Antitumor-like effects on colorectal cancer cells [ 95, 96] No change in apoptosis rate or cell cycle distribution at clinical concentrations [ 97] | Increase in MOR expression in patients with non-small cell lung cancer [ 86] and metastatic lung cancer [ 84] A possible adjuvant therapy of MNTX for patients with advanced cancer [ 88] Intraoperative opioid use is associated with decreased OS in stage I but not stage II-III NSCLC patients [ 94] |
Fentanyl |
Sufentanil |
Others |
COX-2 inhibitor | Antitumor and antiangiogenic properties [ 99] Reduction of ketamine-induced lung metastasis [ 81] | Reduced risk of breast and colorectal cancer [ 100, 101] Use of COX-2 inhibitor was associated with one-fifth reduction in breast cancer recurrence [ 102] |
β-adrenergic antagonist |
Local anesthetics | | |
Lidocaine | Antitumor effect of lidocaine via the inhibition of EGF/EGFR pathway in human tongue cancer cells [ 105] Apoptotic cell death by lidocaine and bupivacaine in breast cancer cells [ 106] Demethylation of DNA in breast cancer cell lines [ 108] Inhibition of cancer cell invasion [ 109] Reduced proliferation of mesenchymal stem cells [ 104] Decreased metastatic progression in breast tumor cells [ 107] Reduced proliferation of MSCs [ 104] No change in apoptosis rate or cell cycle distribution at clinical concentrations [ 97] | |
Lidocaine/tetracaine |
Ropivacaine/bupivacaine |